Kim Richard, Aucejo Federico
Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA.
J Gastrointest Cancer. 2011 Mar;42(1):50-3. doi: 10.1007/s12029-010-9196-2.
No standard therapies have been established for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation.
Sirolimus is a mTOR inhibitor which has been used as an immunosuppressive medication in patients who are at high risk of tumor reoccurrence after liver transplantation. Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC. However the role of sorafenib in patients with HCC reoccurrence after liver transplantation is unclear.
Combination of sirolimus and sorafenib appears to have synergistic effect when treating HCC in preclinical settings. We report a case of a post-liver transplant patient treated with sorafenib and sirolimus for hepatic HCC recurrence who exhibited complete radiologic response after 5A months of therapy.
对于肝移植后复发性肝细胞癌（HCC）的治疗，尚未确立标准疗法。
西罗莫司是一种mTOR抑制剂，已被用作肝移植后肿瘤复发高危患者的免疫抑制药物。索拉非尼是一种多激酶抑制剂，被批准用于治疗晚期HCC。然而，索拉非尼在肝移植后HCC复发患者中的作用尚不清楚。
在临床前研究中，西罗莫司和索拉非尼联合使用在治疗HCC时似乎具有协同作用。我们报告了一例肝移植后患者，其肝HCC复发后接受索拉非尼和西罗莫司治疗，治疗5个月后影像学显示完全缓解。
